Antibodies News and Research

RSS

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

Novel approaches could lead researchers to develop new vaccine for East Coast fever, malaria

The Nairobi-based International Livestock Research Institute announced today that a global consortium supported by the Bill & Melinda Gates Foundation has been formed to develop a new vaccine against a disease that's devastating cattle herds in sub-Saharan Africa. This highly advanced cattle vaccine project could also help malaria and cancer research in humans.

31 Jan 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

Researchers gain better understanding of HIV infection through electron microscopy

The human intestinal tract, or gut, is best known for its role in digestion. But this collection of organs also plays a prominent role in the immune system. In fact, it is one of the first parts of the body that is attacked in the early stages of an HIV infection. Knowing how the virus infects cells and accumulates in this area is critical to developing new therapies for the over 33 million people worldwide living with HIV. Researchers at the California Institute of Technology are the first to have utilized high-resolution electron microscopy to look at HIV infection within the actual tissue of an infected organism, providing perhaps the most detailed characterization yet of HIV infection in the gut.

30 Jan 2014

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms.

29 Jan 2014

Researchers identify unique area of human brain associated with cognitive powers

Oxford University researchers have identified an area of the human brain that appears unlike anything in the brains of some of our closest relatives.

29 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

Porvair Sciences has announced a new Chromatrap Enzymatic Shearing Kit that contains all the necessary reagents and buffers for up to 10 chromatin preparations.

From Chromatrap® - Porvair Sciences Ltd 27 Jan 2014

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Miltenyi Biotec announced today that the U.S. Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from a matched related donor.

24 Jan 2014

Scientists aim to develop business plan to guide drug development for potential use in patients

What if an experimental treatment for an aggressive breast cancer had the potential to save women's lives, but nobody could use it because there was no money to develop and test it? With funding sources for research and development more scarce than in the past, it is not an unusual situation. It's a problem that Sourav Sinha, a Master's degree candidate at Rutgers' Graduate School of Biomedical Sciences, is working to tackle head-on.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Rice University-based research develops fast biosensor for pathogens in food

An array of tiny diving boards can perform the Olympian feat of identifying many strains of salmonella at once.

23 Jan 2014

Anti-malaria drug combination may help prevent pregnancy complications in women with lupus

An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published in the American Journal of Reproductive Immunology.

23 Jan 2014

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.

21 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest.

From Fluxion Biosciences 21 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.

20 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Antibodies News and Research

New study reveals way to combat drug-resistant tumors

Novel approaches could lead researchers to develop new vaccine for East Coast fever, malaria

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers gain better understanding of HIV infection through electron microscopy

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers identify unique area of human brain associated with cognitive powers

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Scientists aim to develop business plan to guide drug development for potential use in patients

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Rice University-based research develops fast biosensor for pathogens in food

Anti-malaria drug combination may help prevent pregnancy complications in women with lupus

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo